Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 17;16(18):3182. doi: 10.3390/cancers16183182

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Total 10-year costs of treatment sequences by first two lines of treatment in patients without TP53 aberration. ACAL: acalabrutinib, ACAL + O: acalabrutinib in combination with obinutuzumab, BR: bendamustine in combination with rituximab, CAD: Canadian dollars, CLB + O: chlorambucil in combination with obinutuzumab, CLB + R: chlorambucil in combination with rituximab, FCR: fludarabine, cyclophosphamide, rituximab, FR: fludarabine in combination with rituximab, IBRU: ibrutinib, V: venetoclax, VO: venetoclax in combination with obinutuzumab, VR: venetoclax in combination with rituximab. The black horizontal line represents the mean cost of all treatment sequences.